Jornay — CareFirst (Caremark)
Moderate to severe binge-eating disorder (BED)
Preferred products
- Adzenys ER
 - Adzenys XR-ODT
 - Adderall XR
 - Evekeo ODT
 - methylphenidate chewable tablet
 - methylphenidate immediate release
 - Aptensio XR
 - Concerta
 - Cotempla XR-ODT
 - methylphenidate CD
 - Methylphenidate Osmotic Extended-Release
 - Relexxii
 - Ritalin LA
 - Focalin
 - Focalin XR
 
Initial criteria
- For ADHD or ADD: The patient has a diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD).
 - The diagnosis has been appropriately documented (e.g., evaluated by a complete clinical assessment, using DSM-5, standardized rating scales, interviews/questionnaires).
 - If the patient is age ≤ 5 years, the patient continues to have ADHD/ADD symptoms despite participating in evidence-based behavioral therapy (e.g., parent training in behavior management (PTBM), behavioral classroom interventions).
 - For Narcolepsy: The patient has a diagnosis of narcolepsy, and the diagnosis has been confirmed by a sleep study.
 - The requested drug is NOT amphetamine extended-release (Adzenys ER, Adzenys XR-ODT), amphetamine-dextroamphetamine extended-release (Adderall XR), amphetamine sulfate orally disintegrating tablet (Evekeo ODT), methylphenidate chewable tablet, methylphenidate immediate release, methylphenidate extended-release (Aptensio XR, Concerta, Cotempla XR-ODT, methylphenidate CD, Methylphenidate Osmotic Extended-Release, Relexxii, Ritalin LA), dexmethylphenidate (Focalin), or dexmethylphenidate extended-release (Focalin XR).
 - The requested drug is being prescribed by, or in consultation with, a sleep specialist.
 
Reauthorization criteria
- For ADHD or ADD: The patient achieved or maintained improvement in their signs and symptoms of ADHD/ADD from baseline.
 - The patient’s need for continued therapy has been assessed within the previous year.
 - For Narcolepsy: The patient has achieved or maintained improvement in daytime sleepiness with narcolepsy from baseline.
 - The request is NOT for amphetamine extended-release (Adzenys ER, Adzenys XR-ODT), amphetamine-dextroamphetamine extended-release (Adderall XR), amphetamine sulfate orally disintegrating tablet (Evekeo ODT), methylphenidate chewable tablet, methylphenidate immediate release, methylphenidate extended-release (Aptensio XR, Concerta, Cotempla XR-ODT, methylphenidate CD, Methylphenidate Osmotic Extended-Release, Relexxii, Ritalin LA), dexmethylphenidate (Focalin), or dexmethylphenidate extended-release (Focalin XR).